Ernest White, MD
Family Medicine · Paris, TXNPI 1295748283
Payments from drug & device makers
Across 176 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$993
- Pfizer$255
- AbbVie$211
- Merck$196
- Johnson & Johnson$191
- Amgen$171
- plus $1K from 30 others
What the payments were for
- Food & beverage$3,17199%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 44 | $993 |
| Pfizer | 14 | $255 |
| AbbVie(2 entities) | 11 | $211 |
| Merck | 12 | $196 |
| Johnson & Johnson | 12 | $191 |
| Amgen | 10 | $171 |
| Lilly USA, LLC | 10 | $153 |
| Mylan Specialty L.p. | 8 | $112 |
| Boehringer Ingelheim | 6 | $94 |
| AstraZeneca | 5 | $69 |
| Philips North America LLC | 5 | $67 |
| Gilead | 1 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $58 |
| Dexcom, Inc. | 3 | $50 |
| Viiv Healthcare Company | 3 | $50 |
| Sunovion Pharmaceuticals Inc. | 4 | $45 |
| Corcept Therapeutics | 2 | $44 |
| Exact Sciences | 2 | $40 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $33 |
| Lundbeck LLC | 2 | $31 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| Shield Therapeutics Inc | 1 | $23 |
| Scilex Pharmaceuticals Inc. | 1 | $20 |
| Eisai Inc. | 1 | $20 |
| Novartis | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Inogen, Inc. | 1 | $19 |
| Viatris Specialty LLC | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Theratechnologies Inc. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Bayer | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Almatica Pharma LLC | 1 | $13 |
| Boston Scientific | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$111
How this compares
$3,202 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 167 | $146,922 |
| OzempicSemaglutide | 56 | $75,415 |
| MounjaroTirzepatide | 55 | $59,984 |
| EliquisApixaban | 56 | $58,945 |
| JardianceEmpagliflozin | 73 | $58,669 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $55,191 |
| LinzessLinaclotide | 35 | $30,817 |
| RybelsusSemaglutide | 14 | $24,959 |
| InvokanaCanagliflozin | 27 | $21,571 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 22 | $20,037 |
| VraylarCariprazine Hcl | 12 | $18,798 |
| EntrestoSacubitril/Valsartan | 24 | $18,017 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $10,432 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 15 | $10,273 |
| MyrbetriqMirabegron | 14 | $8,822 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta, Symbicort | $69 | $157,210200 claims |
| Lilly USA, LLCMounjaro | $153 | $59,98455 claims |
| PfizerEliquis | $255 | $58,94556 claims |
| Boehringer IngelheimJardiance | $94 | $58,66973 claims |
| GSKTrelegy Ellipta | $993 | $55,19170 claims |
| AbbVieLinzess, Vraylar | $211 | $49,61447 claims |
| Johnson & JohnsonInvokana | $191 | $21,57127 claims |
| MerckJanumet, Janumet Xr | $196 | $20,70531 claims |
| NovartisEntresto | $19 | $18,01724 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $8,82214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Paris
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.